Answers are grounded in this paper and cite their sources.
Extreme hypoxia together with the expression of hypoxia-inducible factor-1α (HIF-1α) represents a significant barrier against the effective photodynamic therapy (PDT) of tumor. To mitigate these issues, we created a core–shell nanosystem that can simultaneously alleviate tumor hypoxia and suppress the expression of HIF-1α to combat tumor resistance against PDT. Specifically, a carrier-free, dual-drug nanocore was formed by the self-assembly of hydrophobic photosensitizer (chlorin e6, Ce6) and rapamycin (RAP), and then the surface was coated by a layer of metal–organic frameworks (MOFs) to load catalase, reaching an overall drug loading of ∼60%. In such system, catalase acted as oxygen-self-supplier to catalyze the decomposition of tumor-abundant H 2 O 2 into O 2, and the sustained release of RAP downregulated HIF-1α, which collectively potentiated the PDT efficacy against tumor. The nanosystem could passively accumulate into tumor, realize in situ oxygen generation and HIF-1α inhibition in tumor tissue, and thus exhibit strong PDT effect toward highly hypoxia tumor. This work provides a highly promising nanoplatform to reverse hypoxia-mediated tumor resistance and overcome the restriction of PDT treatment.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: